A rationally designed neuraminidase immunogen elicits humoral responses to a conserved viral site
Rachel HechtiD, Faez Amokrane Nait MohamediD, Shiyu Zhang, Shaun D. RawsoniD, Saeyoung E. Lee, Connor L. Murphy, Dana N. ThornlowiD, Larance RonsardiD, Timothy M. CaradonnaiD, Daniel LingwoodiD, Aaron G. SchmidtiD
Abstract
Efforts to develop a universal influenza vaccine have primarily focused on the surface-exposed viral hemagglutinin (HA), but neuraminidase (NA) is an additional target for cross-reactive, protective responses. Here, we used hyperglycosylation as an immunogen design approach to reshape anti-NA humoral immunity toward conserved antigenic regions. Iterative design produced a hyperglycosylated NA immunogen that retained enzymatic activity and reactivity to a conformation-specific antibody recognizing the conserved catalytic site. In mice, the hyperglycosylated immunogen elicited serum antibody responses of comparable magnitude to those elicited by the wild-type NA immunogen. However, serum antibodies elicited by the hyperglycosylated immunogen had increased breadth, recognizing N2 NAs from H2N2 and H3N2 viruses spanning nearly 65 years of antigenic drift, as well as a heterosubtypic N9 NA. Single B cell analyses identified a monoclonal antibody that competed with a component of the serum antibody response elicited by the hyperglycosylated immunogen, and structural characterization showed that it recognizes a previously undefined, conserved epitope at the NA tetramer interface. Passive transfer of this interface-directed antibody partially protected mice against lethal heterologous influenza challenge. Collectively, these data show that glycan shielding can reshape and enrich humoral responses toward a conserved antigenic region on NA. The immunogen and hyperglycosylation design strategy described here provide a template for developing next- generation NA-based influenza vaccines. ONE SENTENCE SUMMARYA hyperglycosylated influenza neuraminidase immunogen reshapes humoral immunity and elicits antibodies targeting a conserved tetramer-interface epitope.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Membrane-anchored influenza neuraminidase vaccine drives human-like broadly protective B cell responses
Rui Liu, Chaohui Lin, … Zeli Zhang·bioRxiv·May 15, 2026
- Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation
Xueyong Zhu, Ahmed Magdy Khalil, … James J. Kobie·Communications BiologyPeer-reviewed·Oct 6, 2025
- Modernizing the original influenza vaccine to enhance protective antibody responses against neuraminidase antigens
M. Rakic-Martinez, J. Gao, … R. Daniels·bioRxiv·Feb 20, 2023
- Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3
Gyunghee Jo, Seiya Yamayoshi, … Andrew B. Ward·Nature CommunicationsPeer-reviewed·Aug 1, 2025
- Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability
Mirte N. Pascha, Marlies Ballegeer, … Cornelis A. M. de Haan·bioRxiv·Sep 3, 2024
- Novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase
E. Kirkpatrick Roubidoux, M. McMahon, … F. Krammer·bioRxiv·Feb 26, 2021